AlzeCure Pharma AB (FRA:AC6) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AC6 AlzeCure Pharma AB FRA:AC6
35 GF Score
Price €0.52
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:AC6
35GF Score
AlzeCure Pharma AB FRA:AC6
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
35GF Score

Get the complete analysis for FRA:AC6

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.52
Price